Will New Approaches to Medical Benefit Contracting Help Control Specialty Drug Spend?
Pharmacy benefit contracting has always been a mechanism for payers to offset the cost of small-molecule therapeutic areas. Payers have looked to manufacturers to negotiate contracts that would prevent their products from being placed on a restrictive tier, or subject them to step edits or an NDC block. But with the emergence of biologics driving […]
Market Access Speed Is the Next Critical Differentiator for Pharma Manufacturers
This article was originally published in PharmExec. Over the past decade, the life sciences industry has undergone transformative change that has disrupted everything from early drug discovery to post-launch treatment monitoring. Driven by the proliferation of real-world data (RWD) and technology like AI and machine learning, these innovations are changing our understanding of drug value […]
Navigating HCPCS Coding Changes to Prevent Medical Reimbursement Challenges
When it comes to medical reimbursement, there are several challenges that both payers and providers face in today’s rapidly changing regulatory environment. With new drugs and generics entering the market at breakneck speed and supply chain issues continuing to plague manufacturers, it can be difficult for stakeholders to keep up with the Healthcare Common Procedure […]